Program
efdoralprin alfa
A development code. Also written as “SAR447537”.
In Sanofi’s pipeline, AAT fusion protein
. Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by Sanofi.
Furthest: phase 2, since Mar 28, 20232 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 21 open or running | phase 2since Mar 28, 2023 | Mar 28, 2023 | Jun 30, 2028phase 2 · NCT05897424 |
- Named in Sanofi’s own pipeline as
efdoralprin alfa
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2023First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT05856331 · 99 enrolled · United States, Australia, Denmark and more
- May 31, 2023Phase 2 study in alpha 1-Antitrypsin DeficiencyNCT05897424 · 185 enrolled · United States, Australia, Denmark and more
Ahead
- Jun 30, 2028Primary completion: phase 2 study in alpha 1-Antitrypsin DeficiencyNCT05897424
TargetBeta
“AAT fusion protein”the company's pipeline, read by Claude · source
“Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Defic…”study text, read by Claude · the study
Other programs on SERPINA1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensitrelvirrule | Shionogi | phase 3 | 5 |
| CTX460rule | crispr-therapeutics | phase 2 | 1 |
| Proteasome Inhibitor SHY-ONC6rule | shy-therapeutics | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05897424alpha 1-Antitrypsin Deficiency · United States, Australia, Denmark and more | 2 | Active, not recruiting | Jun 30, 2028 | 185 |
| NCT05856331alpha 1-Antitrypsin Deficiency · United States, Australia, Denmark and more | 2 | Completed | Aug 6, 2025 | 99 |
How it is read
Names in the registry
- “SAR447537”, 2 entries
Codes read as this program: SAR447537.
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.